Global Aptamers Market, By Type (DNA-Based Aptamers, RNA-Based Aptamers and XNA-Based Aptamers), Application (Diagnostics, Therapeutics Development, Research and Development and Other Applications), Technology (SELEX, and Other Technologies), End Users (Academic and Government Research Institutes, Biotechnology and Pharmaceutical Companies, Contract Research Organizations and Other End Users) – Industry Trends and Forecast to 2031.
Aptamers Market Analysis and Size
Aptamers market is advancing with innovative applications in therapeutics, diagnostics, and biotechnology. Latest methods integrate SELEX technology for efficient molecule selection. Technological growth includes enhanced chemical modifications for stability and targeting specificity. Market growth is fueled by increasing demand in drug development and personalized medicine, leveraging aptamers' versatility and efficacy.
The global aptamers market size was valued at USD 194.66 million in 2023 and is projected to reach USD 845.97 million by 2031, with a CAGR of 20.16% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (DNA-Based Aptamers, RNA-Based Aptamers and XNA-Based Aptamers), Application (Diagnostics, Therapeutics Development, Research and Development and Other Applications), Technology (SELEX, and Other Technologies), End Users (Academic and Government Research Institutes, Biotechnology and Pharmaceutical Companies, Contract Research Organizations and Other End Users)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Vivonics Inc. (U.S.), TriLink BioTechnologies (U.S.), SomaLogic Operating Co., Inc. (U.S.), NeoVentures Biotechnology Inc. (Canada), Base Pair Biotechnologies (U.S.), AptaTargets SL (Spain), Aptamer Group (U.K.), Aptamer Sciences, Inc. (U.S.), Aptagen, LLC (U.S.), KANEKA CORPORATION (Japan), LUMITOS AG (Germany), AMS Biotechnology (Europe) Limited (U.K.), Creative Biogene (U.S.), ATDBio Ltd (U.K.), NOVAPTECH (U.S.), and 2bind GmbH (Germany)
|
|
Market Opportunities
|
|
Market Definition
Aptamers are short, single-stranded DNA or RNA molecules that bind specifically to target molecules, such as proteins, peptides, or small molecules. They are selected in vitro through a process called systematic evolution of ligands by exponential enrichment (SELEX). Aptamers have diverse applications in diagnostics, therapeutics, and research due to their high specificity, low immunogenicity, and ease of modification.
Aptamers Market Dynamics
Drivers
- Increasing Point-of-Care Testing
The integration of aptamers into point-of-care diagnostic devices is driving market demand by enhancing diagnostic capabilities in decentralized healthcare settings. Their rapid response times and high specificity enable quick and accurate detection of biomarkers, crucial for timely patient management. For instance, aptamer-based biosensors for detecting pathogens like SARS-CoV-2 offer rapid, reliable results at the point of need, underscoring their role in improving healthcare accessibility and efficiency globally.
- Increasing Demand for Personalized Medicine
Aptamers play a pivotal role in personalized medicine by targeting specific biomarkers or genetic variations unique to individual patients. For instance, aptamers designed to bind to mutated proteins in cancer cells can guide personalized treatments, improving therapeutic outcomes while minimizing side effects. This ability to tailor aptamers to patient-specific profiles enhances their relevance in precision medicine, driving demand in oncology and other fields where personalized treatment strategies are increasingly valued.
Opportunities
- Advancements in SELEX Technology
Advancements in SELEX technology have revolutionized the aptamers market by enabling the development of aptamers with superior binding affinities and specificities. For instance, researchers have utilized modified SELEX protocols to engineer aptamers targeting complex molecules such as proteins or small molecules with high precision. These advancements not only enhance the efficacy of aptamer-based therapeutics but also open doors for new diagnostic applications, thereby expanding the market's potential.
- Targeted Drug Delivery
Targeted drug delivery using aptamers presents a significant market opportunity by enhancing therapeutic efficacy while minimizing off-target effects. For instance, AS1411, an aptamer targeting nucleolin, has been conjugated to doxorubicin nanoparticles for specific delivery to cancer cells, reducing systemic toxicity. Such innovations pave the way for precision medicine approaches, where aptamer-conjugated therapies offer tailored treatments with improved patient outcomes, driving demand for aptamers in therapeutic applications.
Restraints/Challenges
- High Development Costs
The high development costs associated with aptamer research and development pose a significant barrier to market growth. These costs arise from the specialized technologies and expertise required in molecular biology and chemistry. This financial burden limits the accessibility and affordability of aptamers for potential applications, hindering their widespread adoption across various sectors including diagnostics and therapeutics.
- Competition from Antibodies
The established use of antibodies in diagnostics and therapeutics poses a significant hurdle for the aptamers market. Antibodies have a long history of successful application, widespread acceptance, and established manufacturing processes. This familiarity and trust among healthcare professionals and patients create a formidable barrier for aptamers, limiting their adoption and market penetration.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In March 2022, Aptamer Sciences selected a candidate material for the 'Corona-19 virus neutralizing aptamer, supporting non-clinical efforts in COVID-19 treatment and vaccine development
- In July 2021, Aptamer Sciences identified a candidate for the 'Corona 19 virus neutralizing aptamer,' advancing it as non-clinical support for COVID-19 treatment and vaccine development
- In June 2021, Aptamer Group Limited partnered with PinotBio to develop Optimer-drug conjugates, combining Optimer technology with PinotBio's FL-118 compound for targeted oncology therapy
- In March 2021, AstraZeneca extended its collaboration with Aptamer Group to explore new aptamers for delivering drug molecules to renal cells, enhancing oligonucleotide drug delivery research
Aptamers Market Scope
The market is segmented on the basis type, application, technology, and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- DNA-Based Aptamers
- RNA-Based Aptamers
- XNA-Based Aptamers
Application
- Diagnostics
- Therapeutics Development
- Research and Development
- Other Applications
Technology
- SELEX
- Other Technologies
End Users
- Academic and Government Research Institutes
- Biotechnology and Pharmaceutical Companies
- Contract Research Organizations
- Other End Users
Aptamers Market Regional Analysis/Insights
The market is analysed and market size insights and trends are provided by country, type, application, technology, and end-user as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to dominate the aptamers market, continuing its trend due to a sophisticated technological base and increased funding for technology advancement. Rising research and development activities further bolster market growth in the region.
Asia-Pacific is expected to show a rapid growth in the aptamers market due to concerted efforts by market players to penetrate untapped regions and emerging economies. This region benefits from increasing research activities and technological advancements, fostering a favorable environment for the adoption of aptamer-based technologies across various applications.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.
Competitive Landscape and Aptamers Market Share Analysis
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Some of the major players operating in the market are:
- Vivonics Inc. (U.S.)
- TriLink BioTechnologies (U.S.)
- SomaLogic Operating Co., Inc. (U.S.)
- NeoVentures Biotechnology Inc. (Canada)
- Base Pair Biotechnologies (U.S.)
- AptaTargets SL (Spain)
- Aptamer Group (U.K.)
- Aptamer Sciences, Inc. (U.S.)
- Aptagen, LLC (U.S.)
- KANEKA CORPORATION (Japan)
- LUMITOS AG (Germany)
- AMS Biotechnology (Europe) Limited (U.K.)
- Creative Biogene (U.S.)
- ATDBio Ltd (U.K.)
- NOVAPTECH (U.S.)
- 2bind GmbH (Germany)
SKU-